CENTOGENE and Evotec Unveil Potential Gaucher Disease Treatment
Company Announcements

CENTOGENE and Evotec Unveil Potential Gaucher Disease Treatment

Centogene N.V. (CNTG) has released an update.

CENTOGENE N.V. and Evotec SE have discovered a promising new molecule that could potentially treat neuronopathic Gaucher disease. The two companies have extended their partnership, with Evotec leading the next phase of pre-clinical research and holding an exclusive option to acquire CENTOGENE’s share of the IP. If exercised, this could result in license fees, milestone payments, and royalties for CENTOGENE, although financial specifics remain undisclosed.

For further insights into CNTG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCentogene NV Announces Nasdaq Delisting
TheFlyCentogene receives delisting notice from Nasdaq
TheFlyCentogene publishes ROPAD study data on Parkinson’s disease in Brain
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App